Similarly, Nabet et al20 analyzed the data from 273 patients with non–small cell lung cancer receiving PD-1 antibody therapy and found that the initial response assessment by conventional imaging could not fully identify which patients could achieve DCB. This evidence concerns the gene PDCD1 and lung cancer.